On July 17 2018, Green Valley announced that GV-971 met the primary endpoint in the phase III clinical trial.
Established a US-based artificial intelligence team led by senior scientist from Banner Alzheimer 's Institute (BAI), to create a precise diagnosis and treatment platform for brain diseases.
Completed patient enrollment for Phase III clinical trial study of the 971 Project. The speed of patient enrollment broke the record of international clinical studies on Alzheimer's disease.
Green Valley set up the Expert Academician Workstation and the Shenyang Pharmaceutical University Graduate and Postgraduate Student Practice Base, so as to speed up the platform construction of China’s innovative medicine development by integrating intellectual resource from leading scientists and universities.
Initiated cooperation with Shanghai Brain Health Foundation, and launched a 30-year senile brain health cohort study covering 100,000 people, aiming to promote development of brain disease study through digging out key risk factors of Alzheimer's disease and other brain diseases
Signed long-term strategic partnership with Quintiles, the world's largest biopharmaceutical development and business outsourcing service provider, to carry out close cooperation in clinical research worldwide.
Signed strategic cooperation agreement with Shenyang Pharmaceutical University to establish systematic and long-term strategic cooperation in talent training, transformation of scientific and technological achievements, etc.
Inaugurated Green Valley (Benxi) Biopharmaceutical Industrial Base, with aiming to build a research and manufacturing site of carbohydrate drugs.
Completed 971 clinical trial study (Phase II)
Salvianolate entered into NRDL.
Green Valley acquired the 971 Project.
Established “Green Valley Innovation Fund” at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, for research and development of China’s innovative drugs.
Established Green Valley Research Institute in cooperation with Shanghai Institutes for Biological Sciences and Shanghai Institute of Materia Medica, Chinese Academy of Sciences.
Salvianolate injection received SFDA approval.
built up the manufacturing site called ‘Green Valley Life Park’.
Restructured Green Valley Group and established Shanghai Green Valley Pharmaceutical Co., Ltd., in cooperation with the Shanghai Institute of Materia Medica